Antineoplastic AgentsDrug Screening Assays, AntitumorLeukemia P388Antineoplastic Agents, PhytogenicAntibiotics, AntineoplasticEllipticinesDoxorubicinSarcoma 180Amaryllidaceae AlkaloidsCell Line, TumorXenograft Model Antitumor AssaysLeukemia L1210NarcissusBibenzylsTumor Cells, CulturedNeoplasmsAntineoplastic Agents, AlkylatingApoptosisCell SurvivalCisplatinDrug SynergismMolecular StructureBryostatinsThiadiazinesAminoacridinesGalliumMice, NudeDepsipeptidesPaclitaxelNeoplasms, ExperimentalAncitabineNeoplasm TransplantationDose-Response Relationship, DrugLactonesCell DivisionDaunorubicinDrug Evaluation, Preclinical6-MercaptopurineEpothilonesDrug Resistance, NeoplasmFluorouracilAntimetabolites, AntineoplasticCell ProliferationAntineoplastic Combined Chemotherapy ProtocolsStructure-Activity RelationshipProdrugsCell CycleCamptothecinBleomycinEtoposideLung NeoplasmsDrug ResistanceAmsacrineEnzyme InhibitorsBiotransformationColonic NeoplasmsMacrolidesStereoisomerismDrug EvaluationMelanoma, ExperimentalDrug Administration ScheduleMethotrexateInhibitory Concentration 50HL-60 CellsDNA DamageIsoquinolinesBreast NeoplasmsDNAVincristineCell LineTime FactorsMice, Inbred BALB CStreptonigrinCyclophosphamideDioxolesStilbenesOvarian NeoplasmsKineticsIntercalating AgentsLeukemiaPyronesTopoisomerase I InhibitorsTriaziquoneMaytansineTransplantation, HeterologousAcridinesCaspasesNitrogen Mustard CompoundsDrug DesignDrug InteractionsProstatic NeoplasmsLeukemia L5178DNA Topoisomerases, Type IINaphthacenesAcridonesTopoisomerase II InhibitorsClinical Trials as TopicCells, CulturedCarcinoma, Ehrlich TumorTaxoids